For example, Fu et al. found no significant increase in the risk of hospitalization due to HF comparing DPP-4 inhibitors to sulfonylureas [1, 10], whereas other observational studies have reported lower risk with DPP-4 inhibitors compared to other antihyperglycemic drugs, including sulfonylureas and TZDs [2, 18, 19]. The gene discussed is DPP4; the disease is hydrops fetalis.